Duvelisib: First Global Approval

被引：103
作者：
Blair, Hannah A. [1 ]
机构：
[1] Springer, Private Bag 65901, Auckland 0754, New Zealand
来源：
DRUGS | 2018年 / 78卷 / 17期
关键词：
IPI-145; DUVELISIB; INHIBITOR; PI3K-DELTA; GAMMA; SIGNALS;
D O I：
10.1007/s40265-018-1013-4
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
Duvelisib (Copiktra) is a small-molecule inhibitor of phosphatidylinositol-3 kinase that has been developed as an oral treatment for various cancer indications. In September 2018, duvelisib received its first global approval in the USA for the treatment of adult patients with relapsed or refractory chronic lymphocytic leukaemia (CLL)/small lymphocytic lymphoma (SLL) after at least two prior therapies. Duvelisib was also granted accelerated approval in the USA for the treatment of adult patients with relapsed or refractory follicular lymphoma (FL) after at least two prior systemic therapies. Clinical development for various haematological malignancies is ongoing worldwide, as well as preclinical development for solid tumours in the USA. This article summarizes the milestones in the development of duvelisib leading to these first approvals for CLL/SLL and FL.
引用
收藏
页码：1847 / 1853
页数：7
相关论文
共 18 条
  • [1] The phosphoinositide-3-kinase (PI3K)-delta and gamma inhibitor, IPI-145 (Duvelisib), overcomes signals from the PI3K/AKT/S6 pathway and promotes apoptosis in CLL
    Balakrishnan, K.
    Peluso, M.
    Fu, M.
    Rosin, N. Y.
    Burger, J. A.
    Wierda, W. G.
    Keating, M. J.
    Faia, K.
    O'Brien, S.
    Kutok, J. L.
    Gandhi, V.
    [J]. LEUKEMIA, 2015, 29 (09) : 1811 - 1822
  • [2] Casulo C, 2016, HAEMATOLOGICA, V101, P104
  • [3] Davids M, 2018, 23 C EUR HAEM ASS
  • [4] IPI-145 antagonizes intrinsic and extrinsic survival signals in chronic lymphocytic leukemia cells
    Dong, Shuai
    Guinn, Daphne
    Dubovsky, Jason A.
    Zhong, Yiming
    Lehman, Amy
    Kutok, Jeffery
    Woyach, Jennifer A.
    Byrd, John C.
    Johnson, Amy J.
    [J]. BLOOD, 2014, 124 (24) : 3583 - 3586
  • [5] Flinn I, 2016, BLOOD, V128
  • [6] The phase 3 DUO trial: duvelisib vs ofatumumab in relapsed and refractory CLL/SLL
    Flinn, Ian W.
    Hillmen, Peter
    Montillo, Marco
    Nagy, Zsolt
    Illes, Arpad
    Etienne, Gabriel
    Delgado, Julio
    Kuss, Bryone J.
    Tam, Constantine S.
    Gasztonyi, Zoltan
    Offner, Fritz
    Lunin, Scott
    Bosch, Francesco
    Davids, Matthew S.
    Lamanna, Nicole
    Jaeger, Ulrich
    Ghia, Paolo
    Cymbalista, Florence
    Portell, Craig A.
    Skarbnik, Alan P.
    Cashen, Amanda F.
    Weaver, David T.
    Kelly, Virginia M.
    Turnbull, Barry
    Stilgenbauer, Stephan
    [J]. BLOOD, 2018, 132 (23) : 2446 - 2455
  • [7] Duvelisib, a novel oral dual inhibitor of PI3K-δ,γ, is clinically active in advanced hematologic malignancies
    Flinn, Ian W.
    O'Brien, Susan
    Kahl, Brad
    Patel, Manish
    Oki, Yasuhiro
    Foss, Francine F.
    Porcu, Pierluigi
    Jones, Jeffrey
    Burger, Jan A.
    Jain, Nitin
    Kelly, Virginia M.
    Allen, Kerstin
    Douglas, Mark
    Sweeney, Jennifer
    Kelly, Patrick
    Horwitz, Steven
    [J]. BLOOD, 2018, 131 (08) : 877 - 887
  • [8] Flinn IW, 2015, BLOOD, V126
  • [9] The PRIMO study: A phase 2 study of duvelisib efficacy and safety in patients with relapsed or refractory peripheral t-cell lymphoma (PTCL).
    Horwitz, Steven M.
    Soto, Jasminder
    Youssoufian, Hagop
    Lloyd, Deborah
    Le, Ngocdiep T.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [10] Activity of the PI3K-δ,γ inhibitor duvelisib in a phase 1 trial and preclinical models of T-cell lymphoma
    Horwitz, Steven M.
    Koch, Raphael
    Porcu, Pierluigi
    Oki, Yasuhiro
    Moskowitz, Alison
    Perez, Megan
    Myskowski, Patricia
    Officer, Adam
    Jaffe, Jacob D.
    Morrow, Sara N.
    Allen, Kerstin
    Douglas, Mark
    Stern, Howard
    Sweeney, Jennifer
    Kelly, Patrick
    Kelly, Virginia
    Aster, Jon C.
    Weaver, David
    Foss, Francine M.
    Weinstock, David M.
    [J]. BLOOD, 2018, 131 (08) : 888 - 898
12